Clinical Trial Update: A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing umeclidinium/vilanterol to fluticasone propionate/salmeterol in COPD has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Advair (fluticasone propionate/salmeterol)
• Anoro Ellipta (umeclidinium bromide; vilanterol trifenatate)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-05-29